Overview

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Formoterol Fumarate
Glycopyrrolate
Tiotropium Bromide